Open AccessLinezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study
Author(s) -
Sean Wasserman,
James C.M. Brust,
Mahmoud Tareq Abdelwahab,
Francesca Little,
Paolo Denti,
Lubbe Wiesner,
Neel R. Gandhi,
Graeme Meintjes,
Gary Maartens
Publication year - 2022
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkac019
Subject(s) - linezolid , medicine , toxicity , adverse effect , population , discontinuation , rifampicin , antibacterial agent , pharmacology , tuberculosis , antibiotics , pathology , biology , microbiology and biotechnology , vancomycin , staphylococcus aureus , environmental health , bacteria , genetics
Linezolid is recommended for treating drug-resistant TB. Adverse events are a concern to prescribers but have not been systematically studied at the standard dose, and the relationship between linezolid exposure and clinical toxicity is not completely elucidated.